Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Iobenguane→

Iobenguane PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
77679-27-7
Molecular formula
C8H10IN3
Molecular weight
275.09 g/mol
Drug class
Norepinephrine analogueadrenergic-neuron blocking agent and radiopharmaceutical imaging precursor
Mechanism of action
Taken up by the norepinephrine transporter in adrenergic nerve terminals and stored in presynaptic vesicles, with accumulation in adrenergically innervated tissues and neural-crest-derived tumours. When radiolabelled with iodine-123 or iodine-131, it enables diagnostic imaging or targeted radiotherapy.
Indications / reported uses
  • Diagnostic imaging of pheochromocytoma, neuroblastoma and selected other adrenergic tumours with iodine-123-labelled iobenguane.
  • Targeted radiotherapy of selected unresectable or metastatic pheochromocytoma/paraganglioma with iodine-131-labelled iobenguane, where authorised.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/iobenguane · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c89d3ecc-4f4c-4566-8808-79152344194d · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/iobenguane-i-131

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Norepinephrine analogue; adrenergic-neuron blocking agent and radiopharmaceutical imaging precursor

Mechanism of action

Taken up by the norepinephrine transporter in adrenergic nerve terminals and stored in presynaptic vesicles, with accumulation in adrenergically innervated tissues and neural-crest-derived tumours. When radiolabelled with iodine-123 or iodine-131, it enables diagnostic imaging or targeted radiotherapy.

General use cases

  • Diagnostic imaging of pheochromocytoma, neuroblastoma and selected other adrenergic tumours with iodine-123-labelled iobenguane.
  • Targeted radiotherapy of selected unresectable or metastatic pheochromocytoma/paraganglioma with iodine-131-labelled iobenguane, where authorised.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Iobenguane PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Iobenguane Permitted Daily Exposure (PDE) report (the Iobenguane PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Iobenguane Occupational Exposure Limit (OEL) report (the Iobenguane OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.